Abstract
AbstractMost treatments to alleviate major depression work by either inhibiting human monoamine transporters, vital for the reuptake of monoamine neurotransmitters, or by inhibiting monoamine oxidases, which are vital for their degradation. The analysis of the experimental 3D structures of those antidepressants in their drug formulation state is key to precision drug design and development. In this study, we apply microcrystal electron diffraction (MicroED) to reveal the atomic 3D structures for the first time of five of the most prevalent antidepressants (reboxetine, pipofezine, ansofaxine, phenelzine, bifemelane) directly from the commercially available powder of the active ingredients. Their modes of binding are investigated by molecular docking, revealing the essential contacts and conformational changes into the biologically active state. This study underscores the combined use of MicroED and molecular docking to uncover elusive drug structures and mechanisms to aid in further drug development pipelines.
Publisher
Cold Spring Harbor Laboratory
Reference49 articles.
1. Jeon, S. W. , Amidfar, M. & Kim, Y.-K. Bio-psycho-social risk factors for depression. Major Depressive Disorder: Risk Factors, Characteristics and Treatment Options. New York: Nova Science Publisher, 71–90 (2017).
2. Depression and antidepressants: molecular and cellular aspects
3. History and evolution of the monoamine hypothesis of depression;J. Clin. Psychiatry,2000
4. Molecular Neurobiology for Practicing Psychiatrists, Part 5: How a Leucine Zipper Can Turn On Genes: Immediate-Early Genes Activate Late-Gene Expression in the Brain.
5. Overview of monoamine transporters;Curr. Protoc. Pharmacol,2017